Kornimate/medical-research-clean huggingface dataset:
efficacy study of pde-5 inhibitor and calcium channel inhibitor for the treatment of secondary raynaud phenomenon

Conditions: Raynaud Phenomenon

Summary: the prevalence of raynaud phenomenon (rp), a reversible vaso-constriction with skin discoloration, is 5-10% in general population. often conventional measures such as warming up or minimizing exposure to cold are not enough and many patients require treatment with a vasodilator therapy. a recent study showed a good efficacy and safety profile of sildenafil, a selective inhibitor of cgmp specific phosphodiesterase type 5 (pde5) in rp. here, the investigators aim to examine the efficacy and safety of udenafil, a newer pde5 inhibitor, as compared to amlodipine, a well known calcium channel blocker, in the treatment of secondary rp in korean patients.


Eligibility criteria:
inclusion criteria: * secondary raynaud's phenomenon exclusion criteria: * primary raynaud phenomenon * active infection * hypersensitivity to pde5 inhibitor or calcium chanel blocker (ccb) * elevated ast/alt (3 times above the upper normal limit) * severe renal failure * patients on nitrite or nitric oxide (no) donor treatment * recent history of cerebrovascular accidents, acute myocardial infarction, or coronary artery bypass surgery * hypotension (less than 90/50 mmhg) or uncontrolled hypertension

Keywords: pathological conditions signs and symptoms blood circulation
streamline®surgical system compared to istent inject w® in patients with open-angle glaucoma

Conditions: Open Angle Glaucoma

Summary: a study of the streamline surgical system versus competitor


Eligibility criteria:
inclusion criteria: diagnosis of mild to moderate primary open angle glaucomma exclusion criteria: * other types of glaucoma including but not limited to: normal tension glaucoma, pseudoexfoliative glaucoma, narrow angle glaucoma, traumatic, congenital, malignant, uveitic or neovascular glaucoma. ocular hypertension.

Keywords: glaucoma goniotomy migs
time-lapse monitoring of early embryo development after ovarian stimulation during infertility treatment

Conditions: Infertility, Female

Summary: the number of children conceived by assisted reproductive technology is increasing in nordic countries as well as worldwide. an important factor of success in treatment of infertility is a short "time to pregnancy" with impact on both economical aspects for the society and medical and psychological aspects for the couple. during treatment, success relies on 1) optimal stimulation of growth and maturation of multiple follicles by administration of exogenous follicle stimulating hormone (fsh), and 2) selection of the fertilized egg / embryo with the highest potential of implantation to be transferred to the mother. in the present project stimulation of egg production by human urine derived fsh (fostimon®) and recombinant fsh (puregon®) will be compared. to this end early embryo development and kinetics after fertilization will be evaluated. the system to be used is time-lapse recording of embryo morphology during the first days of embryo development by means of an embryoscope. aim of this study is to investigate if puregon and urinary fostimon have different effect on embryo quality. the hypothesis of the study is that stimulation of egg production by these two types of follicle stimulating hormone does not have the same effect on early embryo quality.


Eligibility criteria:
inclusion criteria: * first or second intracytoplasmic sperm injection (icsi) treatment * bmi 18-32 kg/m² * no previous ovarian hyperstimulation syndrome (ohss) * regular menstrual cycle (cycle length 28 ± 3 days * less than 20 antral follicles evaluated by vaginal ultrasound * s- anti-müller hormone (amh) 10 - 40 pmol/l * has given informed consent

Keywords: fertilization in vitro sperm injections, intracytoplasmic follicle stimulating hormone embryonic development
comparison between tuberculin vaccine and cryotherapy in genital wart patients

Conditions: Genital Wart

Summary: cutaneous and genital warts are common dermatological conditions caused by human papilloma virus. although it is a benign condition it causes disfigurement, has tendency to collect, can be transmitted to others, this makes adequate and timely treatment important, while many warts are resolve spontaneously over several years, most patients seek treatment because the warts are unsightly and often tender or painful.

genital warts are highly contagious sexually transmitted diseases (std) caused by infection of human papilloma virus and, as the most common std in developed countries, can currently be considered to be globally epidemic. it is estimated that the frequency of human papilloma virus infection among women in the world ranges from 2% to 44%. the conventional modalities in treatment of warts include destructive therapies such as salicylic acid, trichloroacetic acid, cryotherapy, silver nitrate, phenol, cantharidin, surgical interventions and laser, antiproliferative agents such as bleomycin, vitamin d analogs, podophyllin, 5 fluorouracil and antiviral agents such as cidofovir and retinoids. there are different mechanisms have been proposed for the resolution of warts with skin test antigens such as mumps, candida, trichophyton both at the injected as well as distant sites. tuberculin: purified protein derivative or tuberculin stimulates the cell mediated immunity non specifically by activating t helper 1 cells, natural killer cells, and cytokine production an increase in interleukin-12 as a process in boosting the cell-mediated immunity contributes to the mechanism of action.

Eligibility criteria:
inclusion criteria: * all types of genital and anal warts will be included in this study especially patients with 5 or more warts and more than 1 cm in size exclusion criteria: * patients with immunodeficient diseases or receiving any immunosuppressive drugs * pregnancy and lactation
tissue repository providing annotated biospecimens for approved investigator-directed biomedical research initiatives

Conditions: Age-Related Macular Degeneration; Allergies; Alpha-Gal Syndrome; Alzheimer Disease; Amyloidosis; Ankylosing Spondylitis; Arthritis; Alopecia Areata; Asthma; Atopic Dermatitis; Autism; Autoimmune Hepatitis; Behcet's Disease; Beta-Thalassemia; Cancer; Celiac Disease; Kidney Diseases; COPD; Crohn Disease; Cystic Fibrosis; Diabetes; Dravet Syndrome; DMD; Fibromyalgia; Graves Disease; Thyroid Diseases; Hepatitis; Hidradenitis Suppurativa; ITP; Leukemia; ALS; Lupus or SLE; Lymphoma; Multiple Sclerosis; Myasthenia Gravis; Heart Diseases; Parkinson Disease; Pemphigus Vulgaris; Cirrhosis; Psoriasis; Schizophrenia; Scleroderma; Sickle Cell Disease; Stroke; Ulcerative Colitis; Vasculitis; Vitiligo

Summary: to collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and preventative methods for specific and complex conditions.


Eligibility criteria:
inclusion criteria: * persons 18 to 85 years of age at the date of informed consent. * if presenting with a history of a specific condition, the diagnosis is confirmable in the medical record or may be confirmed using other forms of verification including self-reporting. * understands the procedures and requirements of the study by providing written informed consent (or verbal assent if a legally authorized representative will sign the icf), including consent for authorization for protected health information disclosure. exclusion criteria: * persons younger than 18 years of age or older than 85 years of age at the date of informed consent. * receipt of blood products 30 days before the study blood draw. * receipt of an investigational (unapproved) drug 30 days before the study blood draw. * a confirmable diagnosis of any medical condition that would increase potential phlebotomy risks. * has donated a unit of blood within the last 2 months at the date of informed consent.
contractile properties of hypertrofic muscles in patients with non-dystrophic myotonia

Conditions: Non-Dystrophic Myotonia; Myotonia Congenita

Summary: in myotonia congenita (mc), mutations in the clcn1 gene coding a key chloride channel expressed in muscle cells cause myotonia. on examination, the myotonia can be demonstrated as delayed muscle relaxation of muscle contractions after mechanical stimulations. existing literature describe no muscle weakness in mc patients, however a recent muscle mri study in non-dystrophic myotonia patients found structural abnormalities in affected muscles when examined using t1 and stir imaging. the question remains whether the signs of structural changes in the muscle are merely due to the myotonia, or long-term effects of elevated stress of the tissue, and if so, whether those changes lead to clinically significant loss of contractile properties of the muscle. this study examines if the contractile properties of myotonic muscles are impaired in mc patients. 40 patients with thomsens disease (n=20) and beckers disease (n=20), respectively, will be included along with 20 healthy controls. peak muscle torque is measured in the hand by hand dynamometer and in the thigh and calf muscles with a biodex system 4 pro dynamometer and the cross-sectional area of the muscles are examined on t1-weighed and dixon-mri-scan. with the obtained data peak torque in strength tests, muscle hypertrophy, fat fraction in muscle tissue and contractility of the muscles, compared with healthy controls, will be assessed.


Eligibility criteria:
inclusion criteria: * age \<18 years * molecularly verified mc (thomsens or beckers disease) exclusion criteria: * conditions that may impair results of the study, evaluated by the investigator * clausphobia * pregnancy or breastfeeding * metallic objects in and around the body that are not mr-compatible
study to determine optimum intravenous starting dose of mircera for treatment of pediatric participants with anemia and chronic kidney disease on hemodialysis

Conditions: Renal Anemia

Summary: this sequential study will assess the efficacy and safety of multiple doses of intravenous (iv) methoxy polyethylene glycol-epoetin beta (mircera), and will determine the optimum starting dose for maintenance treatment of anemia in children with chronic kidney disease on hemodialysis. pediatric participants will remain on epoetin alfa, epoetin beta or darbepoetin alfa during the screening period, after which they will receive iv mircera monthly, at a starting dose related to the previous weekly epoetin or darbepoetin alfa dose. depending on the response achieved, another group may be selected to receive a higher or a lower dose.


Eligibility criteria:
inclusion criteria: * children aged 5-17 years (in russia only: 12-17 years) with clinically stable chronic renal anemia * hemodialysis for greater than or equal to (\>=) 8 weeks * intravenous stable maintenance treatment with epoetin alfa, epoetin beta, or darbepoetin alfa for \>= 8 weeks before screening and with no weekly dose change \>= 25 percent (%) (increase or decrease) during the 2 weeks of screening exclusion criteria: * overt gastrointestinal bleeding within 8 weeks before screening or during the screening period * red blood cell (rbc) transfusions within 8 weeks before screening or during the screening period * active malignant disease * pure red cell aplasia (prca) or history of prca * pregnant or lactating females * sexually active participants: not willing to use reliable contraception during treatment and for 90 days following the end of treatment
the effects of colorectal prehabilitation via reinfusion or retention enema of ileal contents filtrate on the defecation functions for the lar patients with ileostomy before stoma closure

Conditions: Low Anterior Resection Syndrome

Summary: this study was a single-center rct study to compare the effect of preoperative prehabilitation treatment of ileostomy contents filtrate reinfusion through distal ileocolon or retention of enema colon with that of traditional treatment in patients with bowel function after stoma closure.

the patients in the experimental group collected the contents of the ileostomyand placed in a wide mouth container, mixed with 500ml normal temperature saline, and placed in a funnel with double layer medical gauze. the filtrate of the ileal contents was collected and placed into an enema for use. the catheter was placed into the ileal output end of the ostomy through anterograde enema or transanal retention enema, and slowly infused for 15-20 minutes, 2-3 times a day for 4 weeks. the adverse reactions such as abdominal pain, abdominal distension and fever were observed. the number, time, antegrade/retrograde prehabilitation operation, adverse reactions during the operation and other special conditions were recorded every day, and the weight of the patient was recorded.patients in the control group received routine perioperative management.

Eligibility criteria:
inclusion criteria: * aged 18-85 years old * karnofsky performance status (kps)≥70%; or ecog score 2 points or less * rectal cancer confirmed by preoperative pathology * in the rectum resection before low, low colorectal anastomosis or after neoadjuvant therapy of patients * prophylactic ileostomy. exclusion criteria: * cannot complete treatment * the history of the anorectal surgery * preoperative bowel dysfunction such as diarrhea, irritable bowel syndrome and functional constipation, etc.) * postoperative anastomotic fistula and stricture * during pregnancy or breastfeeding women * with uncontrolled seizures, central nervous system disease or a history of mental disorders * the last five years have other history of malignant disease cured except skin cancer and cervical carcinoma in situ * clinically significant (i.e., active) heart disease, such as symptomatic coronary artery disease, new york heart association class ii or worse 9) severe congestive heart failure or major arrhythmia requiring medical intervention, or myocardial infarction within the previous 6 months * has a history of cerebral infarction or cerebral hemorrhage within the past 6 months * organ transplantation requiring immunosuppressive therapy * serious uncontrolled repeated infections, or other serious with disease of control; * moderate or severe renal impairment creatinine clearance equal to or less than 50ml/min, or upper limit of normal (uln) * emergency surgery due to tumor emergencies (bleeding, perforation, obstruction) * in screening the first 4 weeks received study medication or treatment (to participate in other test).
a clinical observation of 1064-nm q-switched fractional laser combined with oral tranexamic acid on treating of melasma.

Conditions: Melasma

Summary: 1.melasma is a common acquired condition of symmetric hyperpigmentation, typically occurring on the face, with higher prevalence in females and darker skin types. treatments for melasma include topical, oral, procedural, and combination treatments. 2.1064-nm q-switched laser is one of the most widely used lasers for pigmented diseases in recent years. this wavelength laser can be effectively absorbed by pigment, which leads to damage of pigment and melanocyte. previous 1064-nm q-switched laser treatment of melasma requires the use of large flare and low energy scanning repeatedly in the lesion area, and the terminal reaction is reddish and skin lesion temperature increased by 2℃. so the course of treatment is even longer and is closely related to the treatment of the doctor's subjective judgment. current 1064-nm q-switched fractional laser is designed with focusing lens and can be scanned only once for skin lesions during treatment. further more, the treatment energy of a single point is higher and it has stronger ability to destroy melanin. finally, 1064-nm q-switched fractional laser promotes the expulsion of melanin particles from the superficial dermis and basal epidermis. 3.tranexamic acid (ta) works by inhibiting the plasmin-plasminogen pathway. increase in plasmin in keratinocytes leads to increase in production of arachidonic acid and alpha-melanocyte-stimulating hormone (alpha-msh) production. thus, by inhibiting the plasmin pathway, ta results in decreased melanogenesis. studies support the use of oral ta as an adjuvant therapy for in refractory cases of melasma or as a second-line or third-line agent, and there is some early evidence supporting the utility of oral ta as monotherapy. overall, randomized controlled trials have found that combination treatment regimens using oral ta as adjunct therapy results in greater reduction of melasma.


Eligibility criteria:
inclusion criteria: .subjects must be clinically diagnosed by the investigator to melasma and masi score ≥24. * no other treatment was performed for the skin lesions for half a year before the treatment * (patients with a "no" in any of the above criteria are not eligible for inclusion) .understand and voluntarily sign an informed consent document prior to any study related assessments/procedures being conducted. exclusion criteria: * subjects with a recent history of exposure to sunlight; * subjects allergic to topical anesthesia; * subjects with scar constitution; * subjects with skin malignant tumors or precancerous lesions; .subjects with diabetes, heart disease, epilepsy, connective tissue disease, etc. * subjects who pregnant or breast feeding; * subjects with recent skin infections (such as viruses, bacteria, etc.); * the methods are being used to treat subjects with similar diseases; * subject who have taken isotretinoin a in the past year; .subject with facial dermatitis.

Keywords: melasma 1064-nm q-switched fractional laser tranexamic acid (ta) treatment
patient blood management - use and outcome

Conditions: Hemorrhage

Summary: study the influence of transfusion related patient blood management program actions on transfusion-related outcome measures and cost.

at the university hospital of zurich, an in-house designed monitoring and feedback system was introduced which electronically registers each transfusion of any allogeneic blood product, be it red blood cells, plasma or platelets as well as corresponding laboratory data. results are reported quarterly to department heads. the investigator analyzes whether the introduction of this monitoring and feedback system as part of a patient blood management program has a significant influence on use of allogeneic blood product transfusions and transfusion-related costs, without compromising patient outcome.

Eligibility criteria:
inclusion criteria: * only case records, all discharged patients of the university hospital of zürich exclusion criteria: * not discharged from our hospital.

Keywords: patient blood management red blood cells platelet
combination of nimotuzumab,capecitabine and radiotherapy for inoperable or recurrent gastric cancer

Conditions: Gastric Cancer; Concurrent Chemoradiotherapy

Summary: the prognosis of patients with inoperable locally advanced or residual/relapsed gastric cancer is rather poor. concurrent capecitabine chemoradiotherapy is safe and recommended. nimotuzumab, an anti-egfr (epidermal growth factor receptor) monoclonal antibody, has shown its antitumor safety and efficiency in many phase i/ii studies. efficiency of combination of these treatment need to be further analyzed.

there is no standard treatment for patients with inoperable locally advanced or residual/relapsed gastric cancer. for the former ones, 5-fluorouracil(5-fu) based concurrent chemoradiotherapy is a recommended treatment regimen. concurrent capecitabine chemoradiotherapy showed similar results. so far, more and more studies have shown that drugs targeting at egfrs play an important role in antitumor treatment. nimotuzumab, an anti-egfr monoclonal antibody, has shown its safety and efficiency in many phase i/ii studies. because of poor survival of patients with inoperable locally advanced or residual/relapsed gastric cancer, the efficiency of nimotuzumab plus concurrent capecitabine chemoradiotherapy need to be further analyzed.

Eligibility criteria:
inclusion criteria: * 18-75 years old, male or female * gastric cancer with measurable lesions, and the diameter is at least 1 cm * karnofsky score: at least 70 * estimated survival: at least 6 months * no prior target therapy or radiotherapy * no severe hypertension, cardiac disease, or diabetes mellitus * normal blood routine and chemical tests * signed consent exclusion criteria: * other malignancies simultaneously except in situ cervix or non-melanoma skin cancer * extensive distant metastases * pregnancy or in lactation * allergic to 5-fluorouracil

Keywords: gastric cancer concurrent chemoradiotherapy target therapy
single and double operator techniques in ultrasound-guided peripheral nerve block learning curve

Conditions: Single-handed Ultrasound-guided Regional Anaesthesia Grip; Single-operator Ultrasound-guided Peripheric Nerve Block; Anesthesiology Training; Jedi Grip

Summary: aim of this study is to compare learning curves of single(1- jedi grip: pappin and christie/ 2- bedforth/ 3- on lock: gupta and berrill) and double operator ultrasound-guided peripheric nerve block techniques on a home-made gelatin-based phantom model.

ultrasound-guided peripheral blocks are conventionaly performed by double operators. one operator controls both the ultrasound probe and peripheric block needle. another assistant operator aspirate or injects local anesthetic. in this technique operator do not sense resistance in the syringe. also this technique requires a well-done communication and coordination between operators. in order to eliminate disadvantages of this technique several single-operator grip techniques of the needle and syringe have been described(1- jedi grip: pappin and christie/ 2- bedforth/ 3- on lock: gupta and berrill). single operator techniques allow the provider to perform independently. aim of this study is to compare learning curves of single and double operator ultrasound-guided peripheric nerve block techniques on a home-made gelatin-based phantom model.

Eligibility criteria:
inclusion criteria: - to be a junior resident of anesthesiology(\< 2 years ) exclusion criteria: * refusal of resident

Keywords: jedi grip single-operator ultrasound-guided regional anaesthesia grip single-handed ultrasound-guided regional anaesthesia 'on lock' grip anesthesiology training